A biopharma company focused on developing and commercializing innovative gene therapies
gensight-biologics.comLinkedInParis, FranceFounded 2012
4 sources · checked 1 time, last 2h ago
The release describes this as a fundraising, not a named financing stage. Heights Capital and Invus are explicitly identified as the two subscribers.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release calls this a “Fundraising” and does not assign a financing stage.
1 source
The source calls this a fundraising but does not state a conventional financing stage. The Paris dateline does not establish headquarters; sources agree.
1 source
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Fundraising | $1.2M ~€2M financing total EUR 1,100,000.19 | 2026-11-19 | not stated | 2 outlets. #56 in Trending |
4 sources · checked 1 time, last 2h ago [ VERIFIED ] read against 4 sources The release describes this as a fundraising, not a named financing stage. Heights Capital and Invus are explicitly identified as the two subscribers. | ||||
Checked against 10 sources yesterday
| Fundraising [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $2.0M €1,694,715.5256 | 2026-03-10 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release calls this a “Fundraising” and does not assign a financing stage. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: businesswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Fundraising [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $3.4M EUR 2,894,715.96 | 2025-12-29 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The source calls this a fundraising but does not state a conventional financing stage. The Paris dateline does not establish headquarters; sources agree. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: businesswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $41.7M €32m | 2013-04-08 | Abingworth, Index Ventures, Novartis, Versant Ventures | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||